Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ZGNX

Zogenix (ZGNX) Stock Price, News & Analysis

Zogenix logo

About Zogenix Stock (NASDAQ:ZGNX)

Key Stats

Today's Range
$26.68
$26.68
50-Day Range
$26.10
$26.68
52-Week Range
$11.03
$26.90
Volume
94 shs
Average Volume
3.76 million shs
Market Capitalization
$1.50 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA.

Receive ZGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zogenix and its competitors with MarketBeat's FREE daily newsletter.

ZGNX Stock News Headlines

Hwasung Industrial Co Ltd 002460
JD Vance Predicts: Wall Street vs. Trump & Your Money
Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.
Alcon (NYSE: ALC)
Longeveron Inc Ordinary Shares - Class A
Biocryst Pharmaceuticals
See More Headlines

ZGNX Stock Analysis - Frequently Asked Questions

Zogenix, Inc. (NASDAQ:ZGNX) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.96) by $0.08. The company's revenue was up 690.6% compared to the same quarter last year.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zogenix investors own include Bristol-Myers Squibb (BMY), QUALCOMM (QCOM), Gilead Sciences (GILD), GW Pharmaceuticals (GWPH), Intel (INTC), Meta Platforms (META) and NVIDIA (NVDA).

Company Calendar

Last Earnings
11/04/2021
Today
11/16/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:ZGNX
CUSIP
98978L10
Employees
218
Year Founded
N/A

Profitability

Net Income
$-209,380,000.00
Net Margins
-278.38%
Pretax Margin
-278.26%

Debt

Sales & Book Value

Annual Sales
$81.69 million
Book Value
$6.64 per share

Miscellaneous

Free Float
53,922,000
Market Cap
$1.50 billion
Optionable
Optionable
Beta
0.89
10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:ZGNX) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners